Current trends in the use of liposomes for tumor targeting
- PMID: 23914966
- PMCID: PMC3842602
- DOI: 10.2217/nnm.13.118
Current trends in the use of liposomes for tumor targeting
Abstract
The use of liposomes for drug delivery began early in the history of pharmaceutical nanocarriers. These nanosized, lipid bilayered vesicles have become popular as drug delivery systems owing to their efficiency, biocompatibility, nonimmunogenicity, enhanced solubility of chemotherapeutic agents and their ability to encapsulate a wide array of drugs. Passive and ligand-mediated active targeting promote tumor specificity with diminished adverse off-target effects. The current field of liposomes focuses on both clinical and diagnostic applications. Recent efforts have concentrated on the development of multifunctional liposomes that target cells and cellular organelles with a single delivery system. This review discusses the recent advances in liposome research in tumor targeting.
Figures





References
-
- Strebhardt K, Ullrich A. Paul Ehrlich's magic bullet concept: 100 years of progress. Nat. Rev. Cancer. 2008;8(6):473–480. - PubMed
-
- Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug. Discov. 2005;4(2):145–160. - PubMed
-
- Elbayoumi T, Torchilin V. Current trends in liposome research. In: Weissig V, editor. Liposomes. Humana Press; NJ, USA: 2010. pp. 1–27. - PubMed
-
■■ Provides a brief overview of various liposomal products currently under development at the experimental and preclinical level.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources